Published • loading... • Updated
EU panel backs earlier use of J&J treatment for multiple myeloma
Summary by rarecancernews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
EU panel backs earlier use of J&J treatment for multiple myeloma
An arm of the European Medicines Agency (EMA) has recommended expanding the European approval of Johnson & Johnson‘s Tecvayli (teclistamab) to treat adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior therapy. The recommendation, which comes from the EMA’s Committee for Medicinal Products for Human Use (CHMP), will now be […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
